Translate this page into:
Metastasis in central nervous system: Clinicopathological study with review of literature in a tertiary care center in South India
*Corresponding author: Dr. Rashmi Patnayak. rashmipatnayak2002@yahoo.co.in
This article was originally published by Thieme Medical and Scientific Publishers Pvt. Ltd. and was migrated to Scientific Scholar after the change of Publisher.
Abstract
Abstract
Background: Secondary central nervous system (CNS) tumors are common in Western countries, but in Indian literature, scant data are available. With the advent of newer imaging techniques, the confirmatory histopathological diagnosis has become comparatively easier. Hereby, we have analyzed our data from a single tertiary care center in south India. Materials and Methods: In this retrospective study from January 2000 to December 2010, histopathologically diagnosed secondary CNS tumors were reviewed along with clinical, imaging, and relevant immunohistochemical findings. Meningeal, lymphoproliferative, and myeloproliferative tumors and autopsy data were not included in the study group. Results: There were 40 secondary CNS tumors. Male to female ratio was 2.3:1. Age range was wide (28-75 years). Majority of cases were seen in the fourth and fifth decade. Imaging-wise, (computed tomography and magnetic resonance imaging) majority were single lesions (n = 34, 85%). Most commonly, these single lesions were present in the cerebral hemisphere (n = 20, 50%) followed by cerebellum (n = 10, 25%). Adenocarcinoma accounted for maximum number of cases (n = 25, 62.5%) with lungs being the most common primary. Conclusion: We have noted 25% metastatic adenocarcinomas in cerebellar location, which is higher when compared with available world literature. However, we also encountered a good number of cases (30%) due to unknown primary. Though histopathological examination with use of immunohistochemical markers can reliably distinguish primary from secondary CNS tumors in addition to available clinical and imaging data, particularly in developing countries, still a better work-up with an array of immunohistochemical markers and newer imaging modalities is desirable.
Keywords
References
- Patchell RA. The management of brain metastases. Cancer Treat Rev 2003;29:533-40.
- Johnson JD, Young B. Demographics of brain metastasis. Neurosurg Clin N Am 1996;7:337-44.
- Subramanian A, Harris A, Piggott K, Shieff C, Bradford R. Metastasis to and from the central nervous system: The ′relatively protected site′. Lancet Oncol 2002;3:498-507.
- Zhang C, Yu D. Microenvironment determinants of brain metastasis. Cell Biosci 2011;1:8.
- Fidler IJ. The role of the organ microenvironment in brain metastasis. Semin Cancer Biol 2011;21:107-12.
- Kamar FG, Posner JB. Brain metastases. Semin Neurol 2010;30:217-35.
- Ascierto PA, Simeone E, Giannarelli D, Grimaldi AM, Romano A, Mozzillo N. Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: A possible algorithm for clinical use. J Transl Med 2012;10:107.
- Gavrilovic IT, Posner JB. Brain metastases: eEpidemiology and pathophysiology. J Neurooncol 2005;75:5-14.
- Salvati M, Frati A, Russo N, Brogna C, Piccirilli M, D′Andrea G, et al. Brain metastasis from prostate cancer. Report of 13 cases and critical analysis of the literature. J Exp Clin Cancer Res 2005;24:203-7.
- Nathoo N, Chahlavi A, Barnett GH, Toms SA. Pathobiology of brain metastases. J Clin Pathol 2005;58:237-42.
- Mut M, Schiff D, Shaffrey ME. Metastasis to nervous system: Spinal epidural and intramedullary metastases. J Neurooncol 2005;75:43-56.
- Altaha R, Crowell E, Hobbs G, Higa G, Abraham J. Increased risk of brain metastases in patients with HER-2/neu-positive breast carcinoma. Cancer 2005;103:442-3.
- Mayer M. A patient perspective on brain metastases in breast cancer. Clin Cancer Res 2007;13:1623-4.
- Almasi S, Bashashati M, Rezaei N, Markazi-Moghaddam N. Brain metastasis from esophageal carcinoma. Neurol India 2004;52:492-3.
- Delattre JY, Krol G, Thaler HT, Posner JB. Distribution of brain metastases. Arch Neurol 1988;45:741-4.
- Pavlidis N, Briasoulis E, Hainsworth J, Greco FA. Diagnostic and therapeutic management of cancer of unknown primary. Eur J Cancer 2003;39:1990-2005.
- DeYoung BR, Wick MR. Immunohistologic evaluation of metastatic carcinomas of unknown origin: An algorithmic approach. Semin Diagn Pathol 2000;17:184-93.
- Drlicek M, Bodenteich A, Urbanits S, Grisold W. Immunohistochemical panel of antibodies in the diagnosis of brain metastases of the unknown primary. Pathol Res Pract 2004;200:727-34.
- Pomjanski N, Grote HJ, Doganay P, Schmiemann V, Buckstegge B, Böcking A. Immunocytochemical identification of carcinomas of unknown primary in serous effusions. Diagn Cytopathol 2005; 3:309-15.